{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Finerenone+%28BAY+94-8862%29&page=2", "query": { "intervention": "Finerenone (BAY 94-8862)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Finerenone+%28BAY+94-8862%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Finerenone+%28BAY+94-8862%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T20:21:48.473Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06024746", "title": "A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colorado Prevention Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2024-07-09", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 46, "location_summary": "Fairhope, Alabama • Phoenix, Arizona • Chula Vista, California + 40 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06024746" }, { "nct_id": "NCT07547878", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Lotensin", "type": "DRUG" }, { "name": "Capoten", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "Monopril", "type": "DRUG" }, { "name": "Lisinopril", "type": "DRUG" }, { "name": "Univasc", "type": "DRUG" }, { "name": "Aceon", "type": "DRUG" }, { "name": "Accupril", "type": "DRUG" }, { "name": "Altace", "type": "DRUG" }, { "name": "Mavik", "type": "DRUG" }, { "name": "Edarbi", "type": "DRUG" }, { "name": "Atacand", "type": "DRUG" }, { "name": "Avapro", "type": "DRUG" }, { "name": "Cozaar", "type": "DRUG" }, { "name": "Benicar", "type": "DRUG" }, { "name": "Micardis", "type": "DRUG" }, { "name": "Diovan", "type": "DRUG" }, { "name": "Invokana", "type": "DRUG" }, { "name": "Farxiga", "type": "DRUG" }, { "name": "Jardiance", "type": "DRUG" }, { "name": "Ertugliflozin", "type": "DRUG" }, { "name": "Brenzavvy", "type": "DRUG" }, { "name": "Sotagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 64, "start_date": "2026-04-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07547878" }, { "nct_id": "NCT06008197", "title": "A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure", "Acute Heart Failure" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colorado Prevention Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5200, "start_date": "2024-01-17", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008197" }, { "nct_id": "NCT06033950", "title": "A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colorado Prevention Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2600, "start_date": "2024-08-20", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 54, "location_summary": "Fairhope, Alabama • Phoenix, Arizona • Yuma, Arizona + 45 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06033950" }, { "nct_id": "NCT01807221", "title": "Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Inspra (eplerenone)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1066, "start_date": "2013-06-17", "completion_date": "2014-12-09", "has_results": true, "last_update_posted_date": "2021-07-06", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 10, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Macon", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807221" }, { "nct_id": "NCT05348733", "title": "A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Kerendia (Finerenone, BAY94-8862)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4613, "start_date": "2022-06-13", "completion_date": "2026-12-22", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 38, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Harrisburg, Arkansas + 33 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Harrisburg", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Granada Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05348733" }, { "nct_id": "NCT07223502", "title": "A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension (HTN)" ], "interventions": [ { "name": "Combination Product: FDC of spironolactone and ER torsemide", "type": "DRUG" }, { "name": "Combination Product: Stabilized doses of loop diuretic and finerenone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarfez Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-05-01", "completion_date": "2026-09-17", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 1, "location_summary": "Vienna, Virginia", "locations": [ { "city": "Vienna", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223502" }, { "nct_id": "NCT04477707", "title": "A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Retinopathy" ], "interventions": [ { "name": "Finerenone (BAY94-8862)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 206, "start_date": "2020-07-23", "completion_date": "2021-06-25", "has_results": false, "last_update_posted_date": "2022-06-29", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 10, "location_summary": "Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477707" }, { "nct_id": "NCT07155694", "title": "Role of Finerenone in African American Veterans With Diabetic Kidney Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Kidney Disease" ], "interventions": [ { "name": "Finerenone 10 MG", "type": "DRUG" }, { "name": "Empagliflozin 10 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington D.C. Veterans Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "20 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2026-10-01", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07155694" }, { "nct_id": "NCT07348718", "title": "Rubix LS Diabetic Kidney Disease (DKD) Registry Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Kidney Disease (DKD)" ], "interventions": [ { "name": "Kidney-Protective Therapies Used in Routine Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rubix LS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2000, "start_date": "2025-12-15", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-10-07T20:21:48.473Z", "location_count": 1, "location_summary": "Lawrence, Massachusetts", "locations": [ { "city": "Lawrence", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07348718" } ] }